EmboLog® S
Suspension of Degradable Starch Microspheres

EmboLog® S suspension for injection is an adjuvant in the intra-arterial treatment of inoperable liver tumours and lung tumours in combination with cytostatic agents, aiming to optimise the intra-tumoral drug accumulation.

Depending on the size and vascularisation of the tumour, the arterial blood flow and the arteriovenous shunt volume, EmboLog® S can be given at a dosage of 2.5 and 7.5 ml (150 – 450 mg). A maximum dose of 15 ml/900 mg is possible in individual cases. Local chemotherapy can be carried out in several cycles lasting several days at 2 – 6 weeks intervals.
EmboLog® S should be diluted with the ready-to-use active substance solution to roughly double the volume (10 – 30 ml) to obtain a concentration of approximately starch microspheres. 15 – 30 mg/ml. The mixture of EmboLog® S and cytostatic should be administered over around 20 to 30 minutes. It is advisable to check angiography at about 5 to 10-minute intervals to rule out any back-flow of the therapeutic mixture.
When EmboLog® S is used, a desirable, optimal slowing of blood flow in the tumour-bearing organ/organ segment can be recorded individually by angiographic monitoring. To do this, the tip of the catheter used should be positioned selectively near the tumour via the artery of the target organ.

EmboLog® S – References

[1] Vogl T, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U et al. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. Journal of Cancer Research and Clinical Oncology. 2006;132(11):745-755.(A)
[2] Nabil M, Gruber T, Yakoub D, Ackermann H, Zangos S, Vogl TJ. Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results. Eur Radiol. 2008 Jul;18(7):1456–63.(A)
[3] Vogl T, Gruber T, Balzer J, Eichler K, Hammerstingl R, Zangos S. Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study. Radiology. 2009-1;250(1):281-289.(A)
[4] Vogl T, Gruber T, Naguib N, Hammerstingl R, Nour-Eldin N. Liver Metastases of Neuroendocrine Tumors: Treatment With Hepatic Transarterial Chemotherapy Using Two Therapeutic Protocols. American Journal of Roentgenology. 2009-2;193(4):941-947.(A)
[5] Vogl T, Naguib N, Nour-Eldin N, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. European Radiology. 2009;20(1):173-180.(A)
[6] Vogl T, Naguib N, Nour-Eldin N, Mack M, Zangos S, Abskharon J et al. Repeated Chemoembolization Followed by Laser-Induced Thermotherapy for Liver Metastasis of Breast Cancer. American Journal of Roentgenology. 2011;196(1):W66-W72.(A)
[7] Azizi A, Naguib N, Mbalisike E, Farshid P, Emami A, Vogl T. Liver Metastases of Pancreatic Cancer. Pancreas. 2011;40(8):1271-1275.(A)
[8] Vogl T, Naguib N, Lehnert T, Nour-Eldin N, Eichler K, Zangos S et al. Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: Indications, outcomes and role in patient’s management. Gynecologic Oncology. 2012;124(2):225-229.(A)
[9] Vogl TJ, Jost A, Nour-Eldin NA, Mack MG, Zangos S, Naguib NNN. Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. Br J Cancer. 2012 Mar 27;106(7):1274–9.(A)
[10] Wiggermann P, Heibl M, Niessen C, Müller-Wille R, Gössmann H, Uller W, et al. Degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC: Dynamic Contrast-Enhanced Ultrasonography (DCE-US) based evaluation of therapeutic efficacy using a novel perfusion software. Clin Hemorheol Microcirc. 2012;52(2–4):123–9.(B)
[11] Farshid P, Darvishi A, Naguib N, Bazrafshan B, Paul J, Mbalisike E et al. Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites. Future Oncology. 2013;9(3):419-426.(A)
[12] Vogl T, Gruber-Rouh T, Eichler K, Nour-Eldin N, Trojan J, Zangos S et al. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: Local control and survival results. European Journal of Radiology. 2013;82(2):258-263.(A)
[13] Heibl M, Jung EM, Beyer L, Wohlgemuth WA, Stroszczynski C, Wiggermann P. Aggregated time intensity curves after transarterial chemoembolization with degradable starch microspheres: a feasibility study. Clin Hemorheol Microcirc. 2013 Jan 1;55(4):417–21.(B)
[14] Eichler K, Jakobi S, Gruber-Rouh T, Hammerstingl R, Vogl TJ, Zangos S. Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. Eur J Radiol. 2013 Dec;82(12):e816-822.(A)
[15] Wiggermann P, Wohlgemuth WA, Heibl M, Vasilj A, Loss M, Schreyer AG, et al. Dynamic evaluation and quantification of microvascularization during degradable starch microspheres transarterial Chemoembolisation (DSM-TACE) of HCC lesions using contrast enhanced ultrasound (CEUS): a feasibility study. Clin Hemorheol Microcirc. 2013;53(4):337–48.(B)
[16] Gruber-Rouh T, Naguib N, Eichler K, Ackermann H, Zangos S, Trojan J et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. International Journal of Cancer. 2013;134(5):1225-1231.(A)
[17] Vogl T, Kreutzträger M, Gruber-Rouh T, Eichler K, Nour-Eldin N, Zangos S et al. Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: Feasibility and survival rates. European Journal of Radiology. 2014;83(10):1804-1810.(A)
[18] Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, et al. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol JVIR. 2014 Feb;25(2):240–7.(A)
[19] Orlacchio A, Chegai F, Merolla S, Francioso S, Giudice CD, Angelico M, et al. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol. 2015 Jun 28;7(12):1694–700.(B)
[20] Schicho A, Hellerbrand C, Krüger K, Beyer L, Wohlgemuth W, Niessen C et al. Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels. Journal of Clinical and Translational Hepatology. 2016;4(4):288-292.(B)
[21] Schicho A, Pereira P, Haimerl M, Niessen C, Michalik K, Beyer L et al. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget. 2017;8(42):72613-72620.(A)
[22] Vogl T, Mohamed S, Albrecht M, Gruber-Roh T, Lin H, Nour Eldin N et al. Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates. Pancreatology. 2018;18(1):94-99.(A)
[23] Vogl T, Lahrsow M, Albrecht M, Hammerstingl R, Thompson Z, Gruber-Rouh T. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. European Journal of Radiology. 2018;102:138-145.(A)
[24] Schicho A, Pereira P, Michalik K, Beyer L, Stroszczynski C, Wiggermann P. Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. OncoTargets and Therapy. 2018;Volume 11:345-350.(B)
[25] Gruber-Rouh T, Kamal A, Eichler K, Naguib N, Beeres M, Langenbach M et al. Transarterial Chemoembolization (TACE) Using Mitomycin with or without Irinotecan for Hepatocellular Carcinoma in European Patients. Oncology Research and Treatment. 2018;41(7-8):438-442.(B)
[26] Gruber-Rouh T, Schmitt C, Naguib N, Nour-Eldin N, Eichler K, Beeres M et al. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. BMCCancer. 2018;18(1).(B)
[27] Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L et al. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. European Radiology. 2018;29(3):1285-1292.(A)
[28] Larsen F, Jensen B, Nørgaard H, Hermann H, Larsen P, Markussen A et al. Intrahepatic Oxaliplatin and Systemic 5-FU +/– Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer. Oncology. 2019;96(6):299-308.(B)
[29] Lindgaard S, Brinch C, Jensen B, Nørgaard H, Hermann K, Theile S et al. Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. The Breast. 2019;43:113-119.(B)
[30] Lucatelli P, De Rubeis G, Basilico F, Ginanni Corradini L, Corona M, Bezzi M et al. Sequential dual-phase cone-beam CT is able to intra-procedurally predict the one-month treatment outcome of multi-focal HCC, in course of degradable starch microsphere TACE. La radiologia medica. 2019;124(12):1212-1219.(B)
[31] Orlacchio A, Chegai F, Roma S, Merolla S, Bosa A, Francioso S. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study. La radiologia medica. 2019;125(1):98-106.(A)
[32] Goerg F, Zimmermann M, Bruners P, Neumann U, Luedde T, Kuhl C. Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study. CardioVascular and Interventional Radiology. 2019;42(12):1709-1717.(B)
[33] Haubold J, Reinboldt M, Wetter A, Li Y, Ludwig J, Lange C et al. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. RöFo – Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2020.(B)
[34] Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. CardioVascular and Interventional Radiology. 2019;43(3):402-410.(B)
[35] Ziemann C, Roller J, Malter M, Keller K, Kollmar O, Glanemann M et al. Intra-arterial EmboCept S® and DC Bead® effectively inhibit tumor growth of colorectal rat liver metastases. BMC Cancer. 2019;19(1).
[36] Paprottka KJ, Waggershauser T, Rübenthaler J, Paprottka FJ, Clevert DA, Reiser MF, et al. In vitro study of physical properties of various embolization particles regarding morphology before, during and after catheter passage. Clin Hemorheol Microcirc. 2016;64(4):887–98.(A)

*trademark of PharmaCept GmbH

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details and accept the service to view the translations.